Celyad Oncology S.A.
CLYYF
Get informed when a big investor buys or sells
+ FollowMarket Cap$14.24M
Close$
Share Statistics
| Market cap | $14.24 Million |
|---|---|
| Enterprise Value | $9.30 Million |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | -437.12% |
|---|---|
| Return on Assets | -111.10% |
| Return on Invested Capital | -146.91% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 32.29 |
| Enterprise Value to EBIT | -0.61 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.14 |
| Debt to Equity | 0.4 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Celyad Oncology
17 employees
CEO: Filippo Petti Celyad Oncology SA is a clinical-stage biopharmaceutical entity dedicated to the discovery and advancement of chimeric antigen receptor T (CAR-T) cell therapies for cancer treatment. Its prominent clinical programs include CYAD-101, an a...